Drugs / Firsekibart
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07686770 | Aug 2026 → Sep 2027 expected | Kawasaki disease | Children's Hospital of Fudan University | Not yet recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07381465 | Jun 2026 → Dec 2027 expected | systemic lupus erythematosus | Chinese SLE Treatment And Research Group | Active not recruiting | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT07625514 | May 2026 → Aug 2029 expected | gout | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| — | NCT07502105 | May 2026 → Apr 2027 expected | systemic sclerosis | Tongji Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07616531 | May 2026 → Feb 2029 expected | gout | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| — | NCT07535840 | May → Dec 2026 expected | hepatocellular carcinoma | Tongji Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Firsekibart | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07381465 ↗ |
| Action | Inhibit | “anti-IL-1β biologic” NCT07381465 ↗ |
| Modality | Protein / enzyme biologic | “Firsekibart, as a first anti-IL-1β biologic” NCT07381465 ↗ |
| Route | Subcutaneous | “subcutaneous injection of 200mg Firsekibart” NCT07381465 ↗ |